Table 2.

Univariate and multivariate analyses of recurrence-free interval in 69 patients whose NY-ESO-1 antibody responses were evaluated at 12 months.

	Univariate analysis HR (95% CI)	P value	Multivariate analysis HR (95% CI)	P value
Age (years) (≥70 vs. <70)	1.08 (0.48–2.44)	0.85
Sex (female vs. male)	0.79 (0.23–2.64)	0.70
Tumor location (lower, middle vs. upper)	0.93 (0.85–1.02)	0.12
Histology (differentiated vs. other)	0.93 (0.39–2.24)	0.87
Neoadjuvant chemotherapy (yes vs. no)	1.48 (0.44–4.97)	0.52
Procedure (total vs. partial gastrectomy)	2.57 (1.12–5.88)	0.02	4.38 (1.77–10.9)	0.001
pT (3, 4 vs. 0, 1, 2)	1.07 (1.01–1.13)	0.007	1.09 (1.03–1.15)	0.004
pN (2, 3 vs. 0, 1)	1.15 (1.06–1.25)	<0.001	1.08 (0.99–1.17)	0.09
pStage (III, IV vs. 0, I, II)	1.02 (1.01–1.04)	<0.001
NY-ESO-1 antibody status at 12 months (positive vs. negative)	20.6 (4.82–88.0)	<0.001	21.6 (4.75–98.7)	<0.001

HR hazard ratio, CI confidence interval.

Variables with P < 0.05 in univariate analysis were assessed in multivariate analysis.